(RTTNews) - Alpha Tau Medical Ltd. (DRTS), an Israeli oncology therapeutics company, on Monday announced promising interim data from multiple clinical trials involving its Alpha DaRT therapy.
The trials, focusing on pancreatic cancer, head and neck squamous cell carcinoma or HNSCC, and other cancer types, showed significant results in both safety and efficacy.
In pancreatic cancer trials, Alpha DaRT demonstrated a 91% disease control rate and a 19% overall response rate, with improved survival rates compared to historical benchmarks.
The combination of Alpha DaRT and pembrolizumab in HNSCC patients resulted in a 75% objective response rate, surpassing the 19% seen in previous studies.
The company also received approval from the U.S. FDA to conduct a trial combining Alpha DaRT with chemotherapy in metastatic pancreatic cancer patients.
Additionally, the French Ministry of Health granted approval for a study combining Alpha DaRT with capecitabine for locally advanced pancreatic cancer.
No serious adverse events were reported across these trials, underscoring the safety profile of Alpha DaRT.
The strong interim data has driven an increase in Alpha Tau's shares, reflecting growing investor confidence in its innovative cancer treatment.
Cash Position:
As of September 30, 2024, the Company had cash and cash equivalents, short-term deposits and restricted deposits in the amount of $68.4 million. The Company expects that this cash balance will be sufficient to fund anticipated operations for at least two years.
DRTS is currently trading at $4.06 up by 0.74%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
